CeriBell, Inc.
NASDAQ:CBLLMedical - Devices
+$0.25 today
- Market cap
- $995.34M
- Beta
- 0.84
- P/E (TTM)
- -10.9
- EPS (TTM)
- -$1.60
Volume 0.41M
Average 0.29M
CBLL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CeriBell, Inc.NASDAQ: CBLL
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows in line with its trailing trend
Q1 FY2026 research & development of $6.16M rose 45.1% year over year, ahead of the +43.4% change in trailing-twelve-month research & development. Sequentially, it rose 21.7% from the prior quarter. Over 3 fiscal years it compounded at +38.3% a year.
Context
- Research & development amounted to 21.5% of revenue in FY2025, up 0.8 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +45.1% holds above the trailing-twelve-month pace of +43.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.14M USD
- Year-over-year change
- +41.2%
- 3-year CAGR
- +38.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.14M | +41.2% |
| FY2024 | 2024-12-31 | 13.56M | +50.8% |
| FY2023 | 2023-12-31 | 9M | +24.2% |
| FY2022 | 2022-12-31 | 7.24M | — |
Research & Development vs competitors
How CBLL compares with its peers on the latest reported figures
- CBLL's LTM Mar 2026 research & development of $21.06M is the 3rd highest of the 7 companies compared; the peer median is $10.93M.
- Its year-over-year change of +43.4% is the highest of 7, against a peer median of +9.8%.
- Research & development amounts to 22.2% of revenue for CBLL, versus a peer median of 15.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $202.57M | +14.5% | +6.0% | 13.4% | |
| LTM Mar 2026 | $27.64M | +9.2% | +8.3% | 27.8% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $21.06M | +43.4% | +38.3% | 22.2% |
| LTM Mar 2026 | $11.7M | +10.5% | +3.8% | 19.8% | |
| LTM Mar 2026 | $10.15M | +28.6% | +7.7% | 18.1% | |
| LTM Mar 2026 | $6.33M | -47.4% | -11.0% | 4.2% | |
| LTM Mar 2026 | $2.83M | +8.8% | -20.9% | 8.1% | |
| Peer median (excluding CBLL) | $10.93M | +9.8% | +4.9% | 15.8% | |
Competitors are the stored peer set for CBLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 25.92M | 45.23M | 65.44M | 89.06M |
| Cost of Revenue | 4.43M | 7.06M | 8.69M | 10.79M |
| Gross Profit | 21.49M | 38.16M | 56.75M | 78.27M |
| Gross Margin | 82.9% | 84.4% | 86.7% | 87.9% |
| Research & Development | 7.24M | 9M | 13.56M | 19.14M |
| Selling, General & Admin | 50.27M | 59.21M | 82.9M | 117.53M |
| Operating Expenses | 57.51M | 68.2M | 96.46M | 136.68M |
| Depreciation & Amortization | 497K | 847K | 1.14M | 1.34M |
| EBITDA | (35.06M) | (26.51M) | (37.32M) | (50.18M) |
| EBITDA Margin | -135.3% | -58.6% | -57.0% | -56.3% |
| Operating Income | (36.02M) | (30.04M) | (39.71M) | (58.4M) |
| Operating Margin | -139.0% | -66.4% | -60.7% | -65.6% |
| Interest Income | 0 | 0 | 0 | 0 |
| Interest Expense | 1.6M | 2.1M | 1.99M | 1.89M |
| Other Income / Expenses | (1.14M) | 588K | (746K) | 4.99M |
| Income Before Tax | (37.16M) | (29.45M) | (40.46M) | (53.41M) |
| Pre-Tax Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| Income Tax Expense | 2K | 11K | 0 | 0 |
| Net Income | (37.16M) | (29.46M) | (40.46M) | (53.41M) |
| Net Margin | -143.4% | -65.1% | -61.8% | -60.0% |
| EPS (Basic) | (1.59) | (1.26) | (3.39) | (1.46) |
| EPS (Diluted) | (1.59) | (1.26) | (3.39) | (1.46) |
| Weighted Avg Shares | 23.32M | 23.32M | 11.95M | 36.54M |
| Weighted Avg Shares (Diluted) | 23.32M | 23.32M | 11.95M | 36.54M |
CeriBell, Inc.
NASDAQ:CBLL
Intrinsic Alpha fair value
Locked
Current Price
$25.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.